At a glance
ClinicalIndex Comparison RecordN/ACompleted· 244 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS
In Brief
An observational study for Chronic Hepatitis C. Completed, enrolled 244 participants.
Detailed Summary
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO), work productivity and safety data of the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), ± dasabuvir (DSV), ± ribavirin in chronic hepatitis C virus infected participants.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C
Countries--
CollaboratorsIST GmbH, Germany
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartNov 2015
First PostedDec 2015
Primary CompletionMay 2018
TodayJul 2026
First PostedDec 22, 2015
Enrollment StartNov 27, 2015
Primary CompletionMay 23, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.5 years ago